Clinical Trials Logo

Clinical Trial Summary

This trial investigates the changes in physical and functional tests over time in patients with suspected acute graft versus host disease (from a hematologic stem cell transplant) who started treatment with corticosteroids. Sometimes the transplanted cells from a donor can attack the body's normal cells (called graft-versus-host disease). Steroids are used to treat suspected graft-versus-host disease. Steroid myopathy (muscle weakness and fatigue) is a significant side effect of high dose steroid therapy, and can impair activities of daily of life. The goal of this trial is to learn how patients' physical activities and functions change over time while on GVHD-steroid treatment.


Clinical Trial Description

PRIMARY OBJECTIVE: I. To perform a pilot study to estimate the change in six physical and functional tests over time in patients with suspected acute graft-versus-host disease (GVHD) who have been initiated on treatment with corticosteroids. SECONDARY OBJECTIVES: I. To describe and potentially define steroid myopathy by following the patterns of the muscle loss and functional impairment in this population of patients. II. To follow steroid myopathy and describe its incidence, its severity, and the impact on non-relapse mortality in a homogeneous population of patients with suspected acute graft-versus-host disease (GVHD) who have been initiated on treatment with corticosteroids at a quaternary institution in the inpatient and outpatient setting. III. To estimate the adherence to an intermittently supervised exercise program in hematopoietic stem cell transplantation (HSCT) patients who are at risk of developing steroid myopathy. OUTLINE: Patients complete a physical function test over 15 minutes at baseline, and at days 14, 28, and 56. Patients also participate in an 8-week home-based strengthening and walking program consisting of a strengthening/resistance program for 30 minutes, 3 times a week, and walking program for 20-30 minutes at least 3 times a week. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04521777
Study type Interventional
Source M.D. Anderson Cancer Center
Contact
Status Terminated
Phase N/A
Start date October 1, 2015
Completion date March 18, 2021

See also
  Status Clinical Trial Phase
Terminated NCT01140984 - Intra Arterial (IA) Steroids Infusion for Hepatic Acute Hepatic Graft Versus Host Disease (aGVHD) N/A
Completed NCT00803010 - Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation Phase 2
Withdrawn NCT04280471 - Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease Phase 1
Withdrawn NCT02425813 - Methylprednisolone Sodium Succinate in Treating Patients With Acute Graft-versus-Host Disease of the Gastrointestinal Tract Phase 2
Terminated NCT00038792 - Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD Phase 1/Phase 2
Terminated NCT02436460 - A Study of AbGn-168H in Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell Transplant Phase 1
Not yet recruiting NCT01596192 - PETCT for Diagnosing and Monitoring Acute GVHD N/A
Completed NCT00726375 - The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease Phase 3
Recruiting NCT05823675 - Safety and Clinical Activity of Itolizumab in aGVHD Phase 1
Not yet recruiting NCT06386445 - Study on the Serum Metabolic Markers and Early Complications After Allo-HSCT: Cohort Study
Recruiting NCT05443425 - Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies Phase 1
Recruiting NCT03158896 - Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease Phase 1
Not yet recruiting NCT06444022 - hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation Early Phase 1
Active, not recruiting NCT04976699 - CD24Fc for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) Phase 3
Terminated NCT04095858 - Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) Phase 3
Terminated NCT00032773 - Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD Phase 1/Phase 2
Completed NCT02359929 - BMT Autologous MSCs for GvHD Phase 1
Withdrawn NCT00640497 - Anti-CD3 & Anti-CD7 Ricin A Immunotoxin-Combination for Acute Graft Versus Host Disease Phase 1/Phase 2
Completed NCT03491215 - Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease Phase 1/Phase 2
Completed NCT02687646 - Clinical Trial With MSC for Graft Versus Host Disease Treatment Phase 1/Phase 2